MRI based volumetric measurements of vestibular schwannomas in patients with neurofibromatosis type 2: comparison of three different software tools.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 07 2020
14 07 2020
Historique:
received:
30
07
2019
accepted:
25
06
2020
entrez:
16
7
2020
pubmed:
16
7
2020
medline:
23
1
2021
Statut:
epublish
Résumé
Neurofibromatosis type 2 is a neurogenetic disorder with an incidence of about 1:33.000. Hallmarks are bilateral benign vestibular schwannomas, which can lead to deafness or brainstem compression. Volumetric tumor measurements are essential to assess the efficacy of new therapies. We present a statistical and methodical comparison of three volumetric image analysis tools. We performed volumetric measurements on phantoms with predefined volumes (0.1 to 8.0 ml) and tumors seen on 32 head MRI scans from eight NF2 patients with BrainLab, ITK-Snap, or OsiriX. The software was compared with regard to accuracy and reproducibility of the measurements and time required for analysis. The mean volume estimated by all three software programs differed significantly from the true volume of the phantoms, but OsiriX and BrainLab gave estimates that were not significantly different from each other. For the actual tumors, the estimated volumes with all three software tools showed a low coefficient of variability, but the mean volume estimates differed among the tools. OsiriX showed the shortest analysis time. Volumetric assessment of MRI images is associated to an intrinsic risk of miscalculation. For precise volumes it is mandatory to use the same volumetric tools for all measurements.
Identifiants
pubmed: 32665659
doi: 10.1038/s41598-020-68489-y
pii: 10.1038/s41598-020-68489-y
pmc: PMC7360562
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11541Références
Evans, D. G. et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J. Med. Genet. 29, 841–846 (1992).
doi: 10.1136/jmg.29.12.841
Evans, D. G. R. Neurofibromatosis type 2 (NF2) A clinical and molecular review. Orphanet J. Rare Dis. 4, 16. https://doi.org/10.1186/1750-1172-4-16 (2009).
doi: 10.1186/1750-1172-4-16
pubmed: 19545378
pmcid: 2708144
von Kirschbaum, C. & Gürkov, R. Audiovestibular function deficits in vestibular schwannoma. BioMed Res. Int. 2016, 4980562. https://doi.org/10.1155/2016/4980562 (2016).
doi: 10.1155/2016/4980562
Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358–367. https://doi.org/10.1056/NEJMoa0902579 (2009).
doi: 10.1056/NEJMoa0902579
pubmed: 19587327
pmcid: 4816642
Blakeley, J. O. et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J. Clin. Oncol. 34, 1669–1675. https://doi.org/10.1200/JCO.2015.64.3817 (2016).
doi: 10.1200/JCO.2015.64.3817
pubmed: 26976425
pmcid: 4872317
Farschtschi, S., Kollmann, P., Dalchow, C., Stein, A. & Mautner, V.-F. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur. Arch. Oto-Rhino-Laryngol. 272, 3857–3860. https://doi.org/10.1007/s00405-015-3604-y (2015).
doi: 10.1007/s00405-015-3604-y
Huang, V. et al. Improvement in patient-reported hearing after treatment with bevacizumab in people with neurofibromatosis type 2. Otol. Neurotol. 39, 632–638. https://doi.org/10.1097/MAO.0000000000001781 (2018).
doi: 10.1097/MAO.0000000000001781
pubmed: 29649040
pmcid: 6642810
Mautner, V.-F. et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-oncology 12, 14–18. https://doi.org/10.1093/neuonc/nop010 (2010).
doi: 10.1093/neuonc/nop010
pubmed: 20150363
Riina, H. A. et al. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in Neurofibromatosis type 2. Interv. Neuroradiol. 18, 127–132. https://doi.org/10.1177/159101991201800201 (2012).
doi: 10.1177/159101991201800201
pubmed: 22681725
pmcid: 3380388
Cai, W. et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 250, 665–673. https://doi.org/10.1148/radiol.2503080700 (2009).
doi: 10.1148/radiol.2503080700
pubmed: 19244040
Harris, G. J. et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62, 1314–1319. https://doi.org/10.1227/01.neu.0000333303.79931.83 (2008) (discussion 1319-20).
doi: 10.1227/01.neu.0000333303.79931.83
pubmed: 18824998
Lawson McLean, A. C., McLean, A. L. & Rosahl, S. K. Evaluating vestibular schwannoma size and volume on magnetic resonance imaging: an inter- and intra-rater agreement study. Clin. Neurol. Neurosurg. 145, 68–73. https://doi.org/10.1016/j.clineuro.2016.04.010 (2016).
doi: 10.1016/j.clineuro.2016.04.010
pubmed: 27101086
Cai, W. et al. (2018) Volumetric MRI analysis of plexiform neurofibromas in neurofibromatosis type 1. Comparison of two methods. Acad. Radiol. 25, 144–152. https://doi.org/10.1016/j.acra.2017.09.004 (2018).
doi: 10.1016/j.acra.2017.09.004
pubmed: 29097016
Despotović, I., Goossens, B. & Philips, W. MRI segmentation of the human brain. Challenges, methods, and applications. Comput. Math. Methods Med. 2015, 450341. https://doi.org/10.1155/2015/450341 (2015).
doi: 10.1155/2015/450341
pubmed: 25945121
pmcid: 4402572
Fabri, D. et al. A quantitative comparison of the performance of three deformable registration algorithms in radiotherapy. Z. Med. Phys. 23, 279–290. https://doi.org/10.1016/j.zemedi.2013.07.006 (2013).
doi: 10.1016/j.zemedi.2013.07.006
pubmed: 23969092
pmcid: 3865361
Heckel, F. et al. On the evaluation of segmentation editing tools. J. Med. Imag. 1, 34005. https://doi.org/10.1117/1.JMI.1.3.034005 (2014).
doi: 10.1117/1.JMI.1.3.034005
Yushkevich, P. A., Yang, G. & Gerig, G. ITK-SNAP. An interactive tool for semi-automatic segmentation of multi-modality biomedical images. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2016, 3342–3345. https://doi.org/10.1109/EMBC.2016.7591443 (2016).
doi: 10.1109/EMBC.2016.7591443
Blakeley, J. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma. Curr. Opin. Otolaryngol. Head Neck Surg. 20, 372–379. https://doi.org/10.1097/MOO.0b013e328357d2ee (2012).
doi: 10.1097/MOO.0b013e328357d2ee
pubmed: 22931905
pmcid: 4778430